IL17A and psoriasis: Of interest, two therapeutic human monoclonal antibodies against IL-17 (mAb AIN457 and LY2439821) have been developed and the clinical trials for uveitis, Crohn’s disease, psoriasis and rheumatoid arthritis are underway [34]–[36].